Tevogen Bio (NASDAQ:TVGN – Get Free Report) and BioCardia (NASDAQ:BCDA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.
Profitability
This table compares Tevogen Bio and BioCardia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tevogen Bio | N/A | -387.78% | 434.75% |
| BioCardia | -1,999.77% | N/A | -278.27% |
Earnings & Valuation
This table compares Tevogen Bio and BioCardia”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tevogen Bio | N/A | N/A | -$70,000.00 | N/A | N/A |
| BioCardia | $428,000.00 | 10.38 | -$11.57 million | ($7.05) | -0.35 |
Risk and Volatility
Tevogen Bio has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Insider & Institutional Ownership
20.6% of BioCardia shares are owned by institutional investors. 56.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings for Tevogen Bio and BioCardia, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tevogen Bio | 0 | 0 | 1 | 0 | 3.00 |
| BioCardia | 0 | 0 | 1 | 0 | 3.00 |
Tevogen Bio currently has a consensus price target of $4.20, indicating a potential upside of 206.57%. BioCardia has a consensus price target of $25.00, indicating a potential upside of 924.59%. Given BioCardia’s higher possible upside, analysts clearly believe BioCardia is more favorable than Tevogen Bio.
Summary
BioCardia beats Tevogen Bio on 5 of the 9 factors compared between the two stocks.
About Tevogen Bio
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
